

Article

Inhibition of Lipopolysaccharide-Induced Inflammatory Signaling by Soft Coral-Derived Prostaglandin A₂ in RAW264.7 Cells

Osamu Ohno , Eika Mizuno, Junichiro Miyamoto, Tomoyuki Hoshina, Takuya Sano and Kenji Matsuno *

Department of Chemistry and Life Science, School of Advanced Engineering, Kogakuin University, 2665-1 Nakano, Tokyo 192-0015, Japan

* Correspondence: ohno@cc.kogakuin.ac.jp (O.O.); matz@cc.kogakuin.ac.jp (K.M.); Tel.: +81-42-628-4493 (O.O.); +81-42-628-4492 (K.M.)

Abstract: Lipopolysaccharide (LPS) is a component of the outer membrane of Gram-negative bacteria and causes inflammatory diseases. We searched MeOH extracts of collected marine organisms for inhibitors of LPS-induced nitric oxide (NO) production in RAW264.7 cells and identified prostaglandin A₂ (PGA₂) as an active compound from the MeOH extract of the soft coral *Lobophytum* sp. PGA₂ inhibited the production of NO and reduced the expression of inducible NO synthase (iNOS) in LPS-stimulated RAW264.7 cells. Although short preincubation with PGA₂ did not inhibit LPS-induced degradation and resynthesis of IκBα, the suppressive effect of PGA₂ was observed only after a prolonged incubation period prior to LPS treatment. In addition, PGA₂-inhibited NO production was negated by the addition of the EP4 antagonist L161982. Thus, PGA₂ was identified as an inhibitor of LPS-induced inflammatory signaling in RAW264.7 cells.

Keywords: LPS; soft coral; PGA₂; RAW264.7

Citation: Ohno, O.; Mizuno, E.; Miyamoto, J.; Hoshina, T.; Sano, T.; Matsuno, K. Inhibition of Lipopolysaccharide-Induced Inflammatory Signaling by Soft Coral-Derived Prostaglandin A₂ in RAW264.7 Cells. *Mar. Drugs* **2022**, *20*, 316. <https://doi.org/10.3390/md20050316>

Academic Editor: Alba Silipo

Received: 9 March 2022

Accepted: 6 May 2022

Published: 9 May 2022

Publisher's Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations.



Copyright: © 2022 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (<https://creativecommons.org/licenses/by/4.0/>).

1. Introduction

Lipopolysaccharide (LPS), one of the most common and potent pathogenic factors in human blood, is an endotoxin derived from the outer membrane of Gram-negative bacteria [1]. When it is released from bacterial cell walls into the blood, LPS binds to Toll-like receptor (TLR) 4, which is expressed in innate immune cells, including macrophages, neutrophils, and natural killer (NK) cells. TLR4 is a pattern-recognition receptor that recognizes the molecular patterns associated with pathogenic compounds such as LPS. LPS activates TLR4 signal transduction, including the nuclear factor-κB (NF-κB) and mitogen-activated protein kinase (MAPK) pathways [2–5]. In particular, NF-κB plays an important role in the development of inflammatory responses by the production of proinflammatory mediators, nitric oxide (NO), and cytokines in macrophages. Activated NF-κB induces the upregulation of inducible NO synthase (iNOS) and the production of NO from the amino acid L-arginine. NO is a signaling molecule that plays a key role in the pathogenesis of inflammation [6]. Furthermore, TLR4 signaling is activated in various inflammatory diseases induced by LPS [7,8]. Thus, searching for molecules that inhibit LPS-induced NO production is a promising strategy for the discovery of new anti-inflammatory agents, and several small-molecule compounds that regulate this signaling have been investigated [9,10]. Marine organisms produce a variety of structurally unique compounds and therefore are attractive sources of drug candidates. Recently, marine natural products chrysamide B and biseokeaniamide A were reported for their anti-inflammatory activity in the inhibition of LPS-induced NO production [11,12]. In this study, we searched for metabolites of marine organisms that inhibit NO production by the LPS-stimulated murine macrophage-like cell line RAW264.7. We identified (15S)-prostaglandin A₂ (PGA₂, Figure 1) from the MeOH extract of the soft coral *Lobophytum* sp. and found that it inhibits LPS-induced inflammatory signaling in RAW264.7 cells.




Figure 1. Structure of (15S)-prostaglandin A₂.

2. Results

2.1. Isolation of PGA₂ from the Soft Coral *Lobophytum* sp.

We screened for inhibitors of LPS-induced NO production by RAW264.7 cells from several hundred samples of marine organisms and found that the MeOH extract of the soft coral *Lobophytum* sp., collected at the coast of Ishigaki City, Okinawa Prefecture, Japan, showed marked inhibitory activity. The active component was isolated by chromatographic separation. Spectroscopic analyses (Figures S1–S3, Supplementary Materials) revealed that the purified compound was identical to PGA₂ (Figure 1) [13–15]. PGA₂ was recently independently isolated from the same genus of soft coral and shown to inhibit LPS-induced production of NO in RAW264.7 cells [16]. However, the mechanism of its inhibitory activity against NO production was not revealed. In the present study, we employed commercially available PGA₂ ((15S)-prostaglandin A₂; Cayman Chemical Company) and analyzed its mechanism of action.

2.2. Inhibition of NO Production by PGA₂ in LPS-Stimulated RAW264.7 Cells

NO production was determined by measuring the nitrite content released into the culture media using Griess reagent. As shown in Figure 2, NO production by RAW264.7 cells could be detected after exposure to 1 µg/mL LPS for 24 h compared with the vehicle control. The addition of PGA₂ prior to LPS stimulation significantly decreased the production of NO by RAW264.7 cells in a concentration-dependent manner (Figure 2A). The IC₅₀ value was 3.19 µM. The results of an MTT assay showed no significant change in cell number after exposure to PGA₂ in the presence of LPS for 24 h. Polymyxin B (PMB), used as a positive control, also showed a significant inhibitory effect on NO production in LPS-stimulated RAW264.7 cells (Figure 2B).




Figure 2. Effects of PGA₂ on LPS-induced NO production in RAW264.7 cells. Cells were pretreated with the indicated concentrations of PGA₂ (A) or PMB (B) for 20 min, followed by treatment with 1 µg/mL LPS for 24 h. NO production in the culture medium was determined using Griess reagent. Columns: NO levels determined by the Griess method; circles: cell numbers determined by MTT assays. Values are the mean ± SD of triplicate determinations. Differences between groups were analyzed using an unpaired *t*-test. # *p* < 0.005 vs. the control group; * *p* < 0.05, ** *p* < 0.01, *** *p* < 0.005 vs. the LPS-treated group.

2.3. Inhibition of LPS-Induced iNOS Expression in RAW264.7 Cells by PGA₂

To further evaluate the mechanisms by which PGA₂ inhibits NO production, we examined the protein expression of iNOS by Western blotting. As shown in Figure 3, the protein levels of iNOS were significantly upregulated in response to 1 µg/mL LPS. PGA₂ reduced the levels of iNOS in LPS-stimulated RAW264.7 cells in a concentration-dependent manner. PMB inhibited the LPS-induced expression of iNOS at a concentration of 1 µM.




Figure 3. Effects of PGA₂ on LPS-induced iNOS expression in RAW264.7 cells. **(A)** RAW264.7 cells (1×10^6) were pretreated with the indicated concentrations of PGA₂ or 1 µM PMB at 20 min prior to exposure to 1 µg/mL LPS for 24 h; then, cell lysates were prepared. Total cellular proteins were resolved by SDS-PAGE, transferred to PVDF membranes, and detected using antibodies specific against iNOS and α-tubulin. **(B)** The density ratios of iNOS to α-tubulin are displayed in a histogram. Values are the mean ± SD of triplicate determinations. Differences between groups were analyzed using an unpaired *t*-test. [#] *p* < 0.005 vs. the control group; ^{*} *p* < 0.05, ^{**} *p* < 0.005, ^{***} *p* < 0.001 vs. the LPS-treated group.

2.4. Effects of PGA₂ on the LPS-Induced Expression of IL-6 in RAW264.7 Cells

Proinflammatory cytokines play an important role in the activation of the inflammatory response. To evaluate the anti-inflammatory effect of PGA₂, the contents of proinflammatory cytokine interleukin-6 (IL-6) in the culture medium of LPS-stimulated RAW264.7 cells were measured by ELISA. As shown in Figure 4, the level of IL-6 was significantly elevated by 1 µg/mL LPS. PGA₂ showed a concentration-dependent inhibitory effect on the LPS-induced production of IL-6 in RAW264.7 cells (IC₅₀ value 9.00 µM).

2.5. Effects of PGA₂ on the Expression Levels of IκB in RAW264.7 Cells

LPS induces the proteasome-mediated degradation of the inhibitor of NF-κB (IκB) to activate NF-κB, which regulates the genes encoding iNOS. Activated NF-κB also binds to the IκB promoter to resynthesize IκB [17]. Accordingly, we examined the effects of PGA₂ against the degradation and resynthesis of IκB using Western blotting. LPS induced the degradation of IκBα at 30 min (Figure 5A), then IκBα synthesis was reactivated after 90 min (Figure 5C). Pretreatment with PGA₂ for 20 min did not inhibit the LPS-induced

degradation of I κ B α , as shown in Figure 5A, and 30 μ M PGA₂ did not inhibit the LPS-induced degradation of I κ B α (Figure 5B). The resynthesis of I κ B α was not inhibited by the presence of 10 μ M PGA₂ (Figure S4) or 30 μ M PGA₂ (Figure 5C). On the other hand, PMB clearly inhibited the LPS-induced degradation of I κ B α (Figure S5). These results demonstrate that PGA₂ does not inhibit the LPS-induced activation of NF- κ B directly.




Figure 4. Effects of PGA₂ on LPS-induced expression of IL-6 in RAW264.7 cells. Cells were pretreated with the indicated concentrations of PGA₂ for 20 min, followed by treatment with LPS for 24 h. The IL-6 contents in the culture medium were determined by ELISA. Values are the mean \pm SD of triplicate determinations. Differences between groups were analyzed using an unpaired *t*-test. # *p* < 0.0001 vs. the control group; * *p* < 0.05, ** *p* < 0.005, *** *p* < 0.0001 vs. the LPS-treated group.




Figure 5. Effects of PGA₂ on LPS-induced degradation of I κ B α . (A) RAW264.7 cells (1×10^6) were pretreated with the indicated concentrations of PGA₂ at 20 min prior to exposure to 1 μ g/mL LPS for 30 min, and the cell lysates were analyzed by Western blotting with antibodies against I κ B α and α -tubulin. (B) RAW264.7 cells (1×10^6) were pretreated with 30 μ M PGA₂ at 20 min prior to exposure to 1 μ g/mL LPS for 30 min. Then, the cell lysates were analyzed by Western blotting with antibodies against I κ B α and α -tubulin. (C) RAW264.7 cells (1×10^6) were preincubated or not with 30 μ M PGA₂ for 20 min, then treated with 1 μ g/mL LPS for the indicated periods. The cell lysates were analyzed by Western blotting with antibodies against I κ B α and α -tubulin.

2.6. Inhibition of LPS-Induced Degradation of I κ B α by Prolonged Treatment with PGA₂

LPS-induced degradation of I κ B α was not inhibited in RAW264.7 cells treated with PGA₂ for 20 min. To determine whether prolonged treatment of cells with PGA₂ affects NF- κ B activation, we studied I κ B α degradation in cells pretreated with 30 μ M PGA₂ for 18 h, followed by an LPS challenge. As shown in Figure 6A, PGA₂ inhibited LPS-induced I κ B α degradation at concentrations above 10 μ M following treatment for 18 h. Although treatment with PGA₂ for 18 h slightly reduced the protein levels of I κ B α , LPS-induced I κ B α degradation was substantially reduced in RAW264.7 cells by prolonged treatment with 30 μ M PGA₂ (Figure 6B). In addition, the expression of I κ B α was unaffected by LPS-stimulation for 90 min in cells pretreated with PGA₂ for 18 h. Thus, PGA₂ retains the ability to suppress I κ B α degradation in LPS-activated RAW264.7 cells following prolonged incubation. These results suggest that indirect mechanisms mediate the anti-inflammatory effects of PGA₂.




Figure 6. Inhibition of LPS-induced degradation of I κ B α by prolonged treatment with PGA₂. (A) RAW264.7 cells (1×10^6) were pretreated with the indicated concentrations of PGA₂ for 18 h prior to exposure to 1 μ g/mL LPS for 30 min; then, the cell lysates were analyzed by Western blotting with antibodies against I κ B α and α -tubulin. (B) RAW264.7 cells (1×10^6) were preincubated or not with 30 μ M PGA₂ for 18 h, then treated with 1 μ g/mL LPS for the indicated periods. The cell lysates were analyzed by Western blotting with antibodies against I κ B α and α -tubulin.

2.7. Effects of L161982 on PGA₂-Inhibited NO Production in LPS-Stimulated RAW264.7 Cells

A previous study identified the PGE₂ receptor EP4 as a receptor of PGA₂ in human pulmonary endothelial cells [18]. Therefore, in this study, we investigated the effect of an EP4 antagonist, L161982, on PGA₂-inhibited NO production in LPS-stimulated RAW264.7 cells. As shown in Figure 7, PGA₂-inhibited NO production was negated by the addition of 10 μ M L161982 to LPS-stimulated RAW264.7 cells pretreated with 1 μ M or 3 μ M PGA₂. These results showed that PGA₂ might inhibit LPS-induced NO production mediated by its receptor EP4 and the de novo synthesis of related proteins in RAW264.7 cells.




Figure 7. Effects of L161982 on PGA₂-inhibited NO production in LPS-stimulated RAW264.7 cells. Cells were pretreated (open columns) or not (solid columns) with 10 μM L161982 for 20 min, followed by treatment with the indicated concentrations of PGA₂ for 20 min. Then, cells were treated with or without 1 μg/mL LPS for 24 h. NO production in the culture medium was determined using Griess reagent. Values are the mean ± SD of triplicate determinations. Differences between groups were analyzed using an unpaired *t*-test. * *p* < 0.05.

3. Discussion

In this study, we searched through the metabolites of marine organisms to identify compounds that can inhibit LPS-induced NO production by RAW264.7 cells. Screening several hundred MeOH extracts of marine organisms led us to identify PGA₂ from the MeOH extract of the soft coral *Lobophytum* sp. PGA₂ decreased LPS-induced NO production without cytotoxicity up to 30 μM (Figure 2A) and suppressed the expression of iNOS in LPS-stimulated RAW264.7 cells (Figure 3). Furthermore, PGA₂ inhibited the LPS-induced production of IL-6 in RAW264.7 cells (Figure 4). PGA₂ did not inhibit LPS-induced IκBα degradation when added 20 min prior to an LPS challenge (Figure 5); rather, the suppressive effect of PGA₂ was observed only after a prolonged incubation period (18 h) prior to LPS treatment (Figure 6). PGA₂-inhibited NO production was negated by the addition of the EP4 antagonist L161982 to LPS-stimulated RAW264.7 cells (Figure 7).

Prostaglandins (PGs) are lipid mediators belonging to the eicosanoid family and are key players in a wide variety of physiological and pathological processes in mammals. PGA₂ has been reported to be produced via the metabolic dehydration of PGE₂ in cultured mammalian cells [19]. Although PGA₂ may be produced non-enzymatically as a rearrangement of PGE₂, it is not clear whether PGA₂ is present in mammals. Our current results might shed light on this matter. There are many reports on the biological activities of PGA₂ in mammalian cells, such as the cell cycle arrest of NIH3T3 cells at the G₁ and G₂/M phase by PGA₂ [20]. PGs have also been discovered in marine invertebrates [21]. The Caribbean gorgonian *Plexaura homomalla* was reported to contain 1 million times higher levels of PGA₂ than that found in most other organisms, suggesting that PGA₂ functions in *P. homomalla* as a chemical defense against predators [22].

PGs function as intracellular signal mediators in the regulation of inflammation and immune responses. Cyclopentenone PGs, including PGA₂, were reported to display particularly anti-inflammatory activities and to interfere with the signaling pathway that leads to the activation of transcription factor NF-κB [21]. PGA₂ reportedly inhibits the production of NO, cytokines, and chemokines by LPS-stimulated microglia and astrocytes [23]. In addition, PGA₂ suppresses LPS-induced inflammatory signaling by inhibiting the NF-κB pathway in human pulmonary endothelial cells. This effect was demonstrated to be mediated by EP4, a PGE₂ receptor [18]. Indeed, PGE₂ and an agonist of EP4 were demonstrated to inhibit the proinflammatory actions of LPS in mouse adult ventricular fibroblasts [24]. EP4 is present in RAW264.7 cells [25], but the inhibitory activity of PGA₂ against LPS-induced inflammatory signaling in macrophages has not been investigated in detail. PGA₁ was reported to be a potent inhibitor of NF-κB activation in human cells and acts by inhibit-

ing the phosphorylation and preventing the degradation of I κ B α . The inhibition of NF- κ B does not require protein synthesis but rather is dependent on the presence of a reactive cyclopentenonic moiety [26]. The inhibitory activity of 15-deoxy- $\Delta^{12,14}$ -PGJ₂ (15d-PGJ₂) on LPS signaling has been well studied. 15d-PGJ₂ exhibits a potent anti-inflammatory effect by binding to p50 of NF- κ B [27,28]. In addition, 15d-PGJ₂ is a high-affinity ligand for peroxisome-proliferator-activated receptor γ (PPAR γ) and has been demonstrated to inhibit the induction of inflammatory response genes, including iNOS and TNF α , in a PPAR γ -dependent manner. Furthermore, the expression of the cytoprotective enzyme heme oxygenase-1 (HO-1) is induced and coincident with the anti-inflammatory action of 15d-PGJ₂, suggesting that the expression of HO-1 contributes to the suppression of LPS-induced I κ B degradation induced by 15d-PGJ₂ [29].

The results of the present and previous studies on PGs suggest that PGA₂ does not suppress LPS-induced NO production by direct interaction with LPS signal transduction factors. Rather, PGA₂ might inhibit LPS-induced I κ B degradation mediated by its receptor and the de novo synthesis of related proteins in RAW264.7 cells. Indeed, PGA₂-inhibited NO production was negated by the addition of the EP4 antagonist L161982 in LPS-stimulated RAW264.7 cells (Figure 7). On the other hand, there is also the possibility that PGA₂ may be transformed into an active form, such as PGA₁, in order to show activity. Regardless, PGA₂ was identified as an inhibitor of LPS-induced inflammatory signaling in the murine macrophage-like cell line RAW264.7. Further research may reveal the detailed mechanism of PGA₂ as an anti-inflammatory agent.

4. Materials and Methods

4.1. Materials

Chemicals and solvents were of the highest grade available and used as received from commercial sources. LPS (*Escherichia coli*, sc-3535) was purchased from Santa Cruz Biotechnology, Inc. (Dallas, TX, USA). PGA₂ ((15S)-prostaglandin A₂) and L161982 were purchased from Cayman Chemical Company (Ann Arbor, MI, USA). Polymyxin B (PMB) was procured from Wako (Tokyo, Japan). Monoclonal antibody against iNOS was purchased from Abcam (Cambridge, MA, USA). Monoclonal antibodies against I κ B α and α -tubulin were procured from Cell Signaling Technology (Danvers, MA, USA). NMR spectra were recorded with a JEOL HNM-ECX400 FT NMR spectrometer (JEOL, Tokyo, Japan). Mass spectra (EIMS) were obtained on a JEOL JMSGC MATE II (JEOL). Optical rotation was measured on a JASCO P-2200 polarimeter (JASCO, Tokyo, Japan) using a microcell (light path, 100 mm). HPLC was carried out using an LC-10AT_{VP} pump (Shimadzu, Tokyo, Japan) with an SPD-10AV_{VP} UV detector (Shimadzu).

4.2. Biological Material

Specimens of the soft coral *Lobophytum* sp. were collected along the coast of Ishigaki Island (24°27'27.3" N, 124°09'54.0" E), Okinawa Prefecture, Japan, in May 2018, and were frozen immediately after collection. Specimens of the soft coral were preserved at the School of Advanced Engineering, Kogakuin University.

4.3. Extraction and Isolation of (15S)-Prostaglandin A₂

The soft coral *Lobophytum* sp. (420 g, wet weight) was extracted with MeOH for 2 weeks. The extract was filtered, concentrated in vacuo, and partitioned between EtOAc and H₂O. The EtOAc layer was concentrated and further partitioned between *n*-hexane and 90% aqueous MeOH. The 90% aqueous MeOH layer, which showed remarkable inhibitory activity against LPS-induced NO production in RAW264.7 cells, was fractionated using ODS silica gel column chromatography (MeOH-H₂O). The 80% aqueous MeOH eluent was then subjected to reversed-phase HPLC (STR ODS-II, Shinwa Chemical Industries, Ltd., Kyoto, Japan; solvent MeOH-H₂O) to give (15S)-prostaglandin A₂ (1.9 mg) as a colorless oil.

4.4. Cell Culture

RAW264.7 cells were cultured at 37 °C with 5% CO₂ in DMEM (Nissui, Tokyo, Japan) supplemented with 10% heat-inactivated fetal bovine serum (HyClone; GE Healthcare HyClone Laboratories, Logan, UT, USA), antibiotic-antimycotic mixed stock solution (1% *v/v*, 100 units/mL penicillin, 100 µg/mL streptomycin, 0.25 µg/mL amphotericin B; Nacalai Tesque, Inc., Kyoto, Japan), 2 mM L-glutamine, and 2.25 mg/mL NaHCO₃.

4.5. Nitric Oxide Determination

NO production was measured as previously reported [30]. RAW264.7 cells were seeded at 1×10^6 cells/mL in 96-well plates and cultured overnight. Then, various concentrations of PGA₂ were added. After treatment with 1 µg/mL LPS, the cells were incubated for 24 h. An aliquot of culture medium (100 µL) was mixed with an equal volume of Griess reagent (1% sulfanilamide and 0.1% *N*-naphthylethylenediamine hydrochloride in 2.5% phosphoric acid). Optical density at 550 nm was measured with a microplate reader (Synergy H1, BioTek, Winooski, VT, USA).

4.6. MTT Assay

The MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium-bromide) assay was performed on cells remaining on the 96-well plates used for NO determination. Briefly, MTT reagent (15 µL at 1.44 mg/mL; Nacalai Tesque, Inc., Kyoto, Japan) was added, and the samples were incubated for 4 h. The formazan crystals formed were dissolved in 100% DMSO, and optical density at 540 nm was measured with a Synergy H1 microplate reader.

4.7. Western Blotting Analysis

RAW264.7 cells (1×10^6 cells) were treated with PGA₂ and stimulated with or without LPS for the desired periods. Then, the cells were scraped off and suspended in RIPA buffer (50 mM Tris-HCl (pH 7.4), 150 mM NaCl, 2 mM EDTA, 100 mM NaF, 2 mM Na₃VO₄, 1% Triton X-100, 1% sodium deoxycholate, 0.1% sodium *n*-dodecyl sulfate (SDS), 1 µg/mL aprotinin, and 1 mM PMSF). The supernatants were combined with 2× sample buffer (125 mM Tris-HCl, 20% glycerol, 0.01% bromophenol blue, and 4% SDS) and 2.5% 2-mercaptoethanol, then electrophoresed in 10% polyacrylamide gels. The gels were electrophoretically transferred to polyvinylidene difluoride (PVDF) membranes (Bio-Rad Laboratories, Inc., Hercules, CA) for 30 min. The membranes were then blocked with 10% BSA and incubated with iNOS, IκBα, or α-tubulin antibody in TBS buffer (20 mM Tris-HCl (pH 7.4), pH 7.6, and 500 mM NaCl) at room temperature for 1 h. The blotted membranes were washed 6 times with 0.1% Tween 20 in TBS buffer and incubated with horseradish-peroxidase (HRP)-conjugated goat anti-rabbit IgG (Abcam) for 1 h. Immunoreactive proteins were visualized by using a luminol-based chemiluminescence assay kit (Chemi-Lumi One L; Nacalai Tesque, Inc., Kyoto, Japan) and an ImageQuant LAS 4000 (GE Healthcare Bio-Sciences AB, Uppsala, Sweden).

4.8. IL-6 Production Assay

RAW264.7 cells (1×10^5 cells) seeded in 24-well plates were treated with PGA₂ for 20 min and stimulated with or without 1 µg/mL LPS for 24 h. The culture medium was used for the measurement of IL-6 production using mouse IL-6 ELISA kit (R&D Systems, Inc., Minneapolis, MN, USA).

4.9. Statistical Analysis

NO determination, MTT assay, WB, and ELISA data are presented as the mean ± SD. A value of $p < 0.05$ was considered statistically significant. An unpaired *t*-test was used to determine the difference between experimental groups. Different letters represent significant differences among experimental groups, and means with the same letter are not significantly different ($p > 0.05$).

5. Conclusions

We searched metabolites of marine organisms for compounds that could inhibit LPS-induced NO production by RAW264.7 cells. PGA₂ was identified from the MeOH extract of the soft coral *Lobophytum* sp. and was demonstrated to inhibit LPS-induced NO production and suppress the expression of iNOS in LPS-stimulated RAW264.7 cells. LPS-induced degradation and resynthesis of IκBα were not inhibited by short preincubation with PGA₂, but LPS-induced IκBα degradation was reduced in cells subjected to prolonged treatment with PGA₂. Furthermore, PGA₂-inhibited NO production was negated by the addition of an EP4 antagonist, L161982, in LPS-stimulated RAW264.7 cells. These results suggest that PGA₂ suppresses LPS signaling not by direct inhibition but by the mediation of its receptor and related protein synthesis in RAW264.7 cells. Thus, PGA₂ was identified as an inhibitor of LPS-induced inflammatory signaling. Further research may reveal the detailed mechanism of PGA₂ as an anti-inflammatory agent.

Supplementary Materials: The following are available online at <https://www.mdpi.com/article/10.3390/md20050316/s1>, Spectral data for PGA₂ isolated from the soft coral *Lobophytum* sp.; Figure S1: ¹H NMR spectrum of PGA₂ isolated from the soft coral *Lobophytum* sp. (400 MHz, CDCl₃); Figure S2: ¹H NMR spectrum of PGA₂ isolated from the soft coral *Lobophytum* sp. (400 MHz, CD₃OD); Figure S3: ¹³C NMR spectrum of PGA₂ isolated from the soft coral *Lobophytum* sp. (100 MHz, CD₃OD); Figure S4: Effects of 10 μM PGA₂ on LPS-induced degradation and resynthesis of IκBα; Figure S5: Effects of PMB on LPS-induced degradation of IκBα.

Author Contributions: O.O. and K.M. conceived and designed the study. E.M., J.M., T.H. and T.S. performed the experiments. E.M. and J.M. analyzed the data. O.O. wrote the manuscript. All authors have read and agreed to the published version of the manuscript.

Funding: This research was funded by the Japan Society for the Promotion of Science (JSPS) Grants-in-Aid for Scientific Research (C) (grant number 21K05295 to Osamu Ohno) from the Ministry of Education, Culture, Sports, Science and Technology, Japan.

Acknowledgments: The authors would like to thank S. Simizu, the Faculty of Science and Technology, Keio University, for his contribution to this work.

Conflicts of Interest: The authors declare no conflict of interest.

References

1. Raetz, C.R.; Whitfield, C. Lipopolysaccharide endotoxins. *Annu. Rev. Biochem.* **2002**, *71*, 635–700. [CrossRef] [PubMed]
2. Chow, J.C.; Young, D.W.; Golenbock, D.T.; Christ, W.J.; Gusovsky, F. Toll-like Receptor-4 Mediates Lipopolysaccharide-induced Signal Transduction. *J. Biol. Chem.* **1999**, *274*, 10689–10692. [CrossRef] [PubMed]
3. Poltorak, A.; He, X.; Smirnova, I.; Liu, M.Y.; Huffel, C.V.; Du, X.; Birdwell, D.; Alejos, E.; Silva, M.; Galanos, C.; et al. Defective LPS signaling in C3H/HeJ and C57BL/10ScCr mice: Mutations in Tlr4 gene. *Science* **1998**, *282*, 2085–2088. [CrossRef] [PubMed]
4. Doyle, S.L.; O’Neill, L.A. Toll-like receptors: From the discovery of NFκB to new insights into transcriptional regulations in innate immunity. *Biochem. Pharmacol.* **2006**, *72*, 1102–1113. [CrossRef] [PubMed]
5. Liu, Y.-C.; Zou, X.-B.; Chai, Y.-F.; Yao, Y.-M. Macrophage Polarization in Inflammatory Diseases. *Int. J. Biol. Sci.* **2014**, *10*, 520–529. [CrossRef] [PubMed]
6. Sharma, J.N.; Al-Omran, A.; Parvathy, S.S. Role of nitric oxide in inflammatory diseases. *Inflammopharmacology* **2007**, *15*, 252–259. [CrossRef]
7. Miller, S.I.; Ernst, R.; Bader, M.W. LPS, TLR4 and infectious disease diversity. *Nat. Rev. Genet.* **2005**, *3*, 36–46. [CrossRef]
8. Joh, E.-H.; Gu, W.; Kim, D.-H. Echinocystic acid ameliorates lung inflammation in mice and alveolar macrophages by inhibiting the binding of LPS to TLR4 in NF-κB and MAPK pathways. *Biochem. Pharmacol.* **2012**, *84*, 331–340. [CrossRef]
9. Matsunaga, N.; Tsuchimori, N.; Matsumoto, T.; Ii, M. TAK-242 (Resatorvid), a Small-Molecule Inhibitor of Toll-Like Receptor (TLR) 4 Signaling, Binds Selectively to TLR4 and Interferes with Interactions between TLR4 and Its Adaptor Molecules. *Mol. Pharmacol.* **2010**, *79*, 34–41. [CrossRef]
10. Chiu, L.C.; Wang, J.Y.; Lin, C.H.; Hsu, C.H.; Lin, L.C.; Fu, S.L. Diterpenoid Compounds Isolated from *Chloranthus oldhamii* Solms Exert Anti-Inflammatory Effects by Inhibiting the IKK/NF-κB Pathway. *Molecules* **2021**, *26*, 6540. [CrossRef]
11. Zhu, L.Q.; Fan, X.H.; Li, J.F.; Chen, J.H.; Liang, Y.; Hu, X.L.; Ma, S.M.; Hao, X.Y.; Shi, T.; Wang, Z. Discovery of a novel inhibitor of nitric oxide production with potential therapeutic effect on acute inflammation. *Bioorg. Med. Chem. Lett.* **2021**, *44*, 128106. [CrossRef] [PubMed]

12. Ohno, O.; Terasaki, T.; Sano, T.; Hitomi, Y.; Miyamoto, J.; Matsuno, K. Inhibitory effects of biseokeaniamide A against lipopolysaccharide-induced signal transduction. *Bioorg. Med. Chem. Lett.* **2020**, *30*, 127069. [[CrossRef](#)] [[PubMed](#)]
13. Chapleo, C.B.; Finch, M.W.; Lee, T.V.; Roberts, S.M.; Newton, R.F. Total synthesis of prostaglandin A₂ involving the reaction of a heterocuprate reagent with an allyl epoxide. *J. Chem. Soc. Perkin Trans. 1* **1980**, 2084–2087. [[CrossRef](#)]
14. Bogaards, J.J.; Venekamp, J.C.; van Bladeren, P.J. Stereoselective conjugation of prostaglandin A₂ and prostaglandin J₂ with glutathione, catalyzed by the human glutathione S-transferases A1-1, A2-2, M1a-1a, and P1-1. *Chem. Res. Toxicol.* **1997**, *10*, 310–317. [[CrossRef](#)]
15. Reina, E.; Ramos, F.A.; Castellanos, L.; Aragon, M.; Ospina, L.F. Anti-inflammatory R-prostaglandins from Caribbean Colombian soft coral *Plexaura homomalla*. *J. Pharm. Pharmacol.* **2013**, *65*, 1643–1652. [[CrossRef](#)]
16. Shen, H.; Liu, X.; Jiang, M.; Luo, G.; Wu, Z.; Chen, B.; Li, J.; Liu, L.; Chen, S. Anti-Inflammatory Cembrane-Type Diterpenoids and Prostaglandins from Soft Coral *Lobophytum sarcophytoides*. *Mar. Drugs* **2019**, *17*, 481. [[CrossRef](#)]
17. Pahl, H.L. Activators and target genes of Rel/NF-κB transcription factors. *Oncogene* **1999**, *18*, 6853–6866. [[CrossRef](#)]
18. Ohmura, T.; Tian, Y.; Sarich, N.; Ke, Y.; Meliton, A.; Shah, A.S.; Andreasson, K.; Birukov, K.G.; Birukova, A.A. Regulation of lung endothelial permeability and inflammatory responses by prostaglandin A₂: Role of EP4 receptor. *Mol. Biol. Cell* **2017**, *28*, 1622–1635. [[CrossRef](#)]
19. Ohno, K.; Fujiwara, M.; Fukushima, M.; Narumiya, S. Metabolic dehydration of prostaglandin E₂ and cellular uptake of the dehydration product: Correlation with prostaglandin E₂-induced growth inhibition. *Biochem. Biophys. Res. Commun.* **1986**, *139*, 808–815. [[CrossRef](#)]
20. Hitomi, M.; Shu, J.; Strom, D.; Hiebert, S.W.; Harter, M.L.; Stacey, D.W. Prostaglandin A₂ blocks the activation of G₁ phase cyclin-dependent kinase without altering mitogen-activated protein kinase stimulation. *J. Biol. Chem.* **1996**, *271*, 9376–9383. [[CrossRef](#)]
21. Di Costanzo, F.; Di Dato, V.; Ianora, A.; Romano, G. Prostaglandins in Marine Organisms: A Review. *Mar. Drugs* **2019**, *17*, 428. [[CrossRef](#)] [[PubMed](#)]
22. Gerhart, D.J. Prostaglandin A₂: An agent of chemical defense in the Caribbean gorgonian *Plexaura homomalla*. *Mar. Ecol. Prog. Ser.* **1984**, *19*, 181–187. [[CrossRef](#)]
23. Storer, P.D.; Xu, J.; Chavis, J.A.; Drew, P.D. Cyclopentenone prostaglandins PGA₂ and 15-deoxy-Δ^{12,14}-PGJ₂ suppress activation of murine microglia and astrocytes: Implications for multiple sclerosis. *J. Neurosci. Res.* **2005**, *80*, 66–74. [[CrossRef](#)] [[PubMed](#)]
24. Bryson, T.D.; Ross, J.; Peterson, E.; Harding, P. Prostaglandin E₂ and an EP4 receptor agonist inhibit LPS-Induced monocyte chemotactic protein 5 production and secretion in mouse cardiac fibroblasts via Akt and NF-κB signaling. *Prostaglandins Other Lipid Mediat.* **2019**, *144*, 106349. [[CrossRef](#)] [[PubMed](#)]
25. Tajima, T.; Murata, T.; Aritake, K.; Urade, Y.; Michishita, M.; Matsuoka, T.; Narumiya, S.; Ozaki, H.; Hori, M. EP₂ and EP₄ receptors on muscularis resident macrophages mediate LPS-induced intestinal dysmotility via iNOS upregulation through cAMP/ERK signals. *Am. J. Physiol. Gastrointest. Liver Physiol.* **2012**, *302*, G524–G534. [[CrossRef](#)] [[PubMed](#)]
26. Rossi, A.; Elia, G.; Santoro, M.G. Inhibition of nuclear factor κB by prostaglandin A₁: An effect associated with heat shock transcription factor activation. *Proc. Natl. Acad. Sci. USA* **1997**, *94*, 746–750. [[CrossRef](#)]
27. Straus, D.S.; Pascual, G.; Li, M.; Welch, J.S.; Ricote, M.; Hsiang, C.H.; Sengchanthalangsy, L.L.; Ghosh, G.; Glass, C.K. 15-Deoxy-Δ^{12,14}-prostaglandin J₂ inhibits multiple steps in the NF-κB signaling pathway. *Proc. Natl. Acad. Sci. USA* **2000**, *97*, 4844–4849. [[CrossRef](#)]
28. Cernuda-Morollón, E.; Pineda-Molina, E.; Cañada, F.J.; Pérez-Sala, D. 15-Deoxy-Δ^{12,14}-prostaglandin J₂ inhibition of NF-κB-DNA binding through covalent modification of the p50 subunit. *J. Biol. Chem.* **2001**, *276*, 35530–35536. [[CrossRef](#)]
29. Lee, T.S.; Tsai, H.L.; Chau, L.Y. Induction of heme oxygenase-1 expression in murine macrophages is essential for the anti-inflammatory effect of low dose 15-deoxy-Δ^{12,14}-prostaglandin J₂. *J. Biol. Chem.* **2003**, *278*, 19325–19330. [[CrossRef](#)]
30. Vodovotz, Y. Modified microassay for serum nitrite and nitrate. *Biotechniques* **1996**, *20*, 390–392. [[CrossRef](#)]